Oncolytics Biotech Inc. (TSE:ONC - Get Free Report)'s stock price traded down 3.4% during mid-day trading on Wednesday . The company traded as low as C$1.10 and last traded at C$1.13. 103,662 shares changed hands during mid-day trading, an increase of 2% from the average session volume of 101,767 shares. The stock had previously closed at C$1.17.
Wall Street Analysts Forecast Growth
Separately, Raymond James raised Oncolytics Biotech to a "moderate buy" rating in a research report on Thursday, November 14th.
Read Our Latest Report on Oncolytics Biotech
Oncolytics Biotech Price Performance
The stock has a market capitalization of C$89.16 million, a P/E ratio of -3.05 and a beta of 1.35. The company has a debt-to-equity ratio of 6.09, a current ratio of 4.99 and a quick ratio of 8.86. The company's 50-day simple moving average is C$1.31 and its 200-day simple moving average is C$1.39.
Oncolytics Biotech Company Profile
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
See Also
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
